Noida/Ghaziabad, For 28-year-old Morifat Rashid, her husband’s decision to donate a kidney brought hope after years of battling an autoimmune disease, kidney failure and repeated health complications. But transplant brought two major challenges high risk of blood clots and antibodies that could attack the donated kidney.
Rashid had good urine output and stable kidney function after the surgery. She was later shifted back to warfarin, with its dose adjusted through regular blood tests.
“Both risks were carefully managed through planned anticoagulation, plasmapheresis and IVIg therapy,” said Dr Prajit Mazumdar, Senior Consultant, Nephrology and Renal Transplant.
Her regular blood-thinning medicine, warfarin, was stopped five days before surgery and replaced with heparin to manage the clotting risk around the operation.
To reduce the antibody-related risk, Rashid underwent three sessions of plasmapheresis, a procedure that removes harmful antibodies from the blood, along with intravenous immunoglobulin therapy before the transplant.
